Blueprint Medicines Corp. (BPMC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151356,
    "name": "Blueprint Medicines Corp.",
    "stock_name": "Blueprint Medicines Corp.",
    "full_name": "Blueprint Medicines Corp.",
    "name_url": "stocks-analysis/blueprint-medicines-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "129.46",
    "chg": 0.18,
    "chgp": "0.14%",
    "dir": 1,
    "prev_price": "129.28",
    "mcapval": "8,371.67",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US09627Y1091",
    "curr_date": "Jul 17",
    "curr_time": "",
    "bse_nse_vol": "5.96 M",
    "exc_status": "Active",
    "traded_date": "Jul 17, 2025",
    "traded_date_str": "2025 07 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/blueprint-medicines-corp-1151356-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Blueprint Medicines Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-blueprint-medicines-corp-technically-bullish-or-bearish-3547308",
        "imagepath": "",
        "date": "2025-09-20 19:52:26",
        "description": "As of 4 June 2025, the technical trend for Blueprint Medicines Corp. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, while the Bollinger Bands also indicate bullishness in both periods. Moving averages are bullish on the daily chart, and Dow Theory confirms a bullish trend on both weekly and monthly levels. However, the weekly RSI is bearish, which suggests some short-term weakness. \n\nIn terms of performance, the stock has returned 48.43% year-to-date compared to the S&P 500's 12.22%, and over three years, it has outperformed the benchmark with a return of 141.76% versus 70.41%. Overall, the technical indicators point to a bullish stance, albeit with some caution due to the bearish weekly RSI...."
      },
      {
        "title": "Is Blueprint Medicines Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-blueprint-medicines-corp-overvalued-or-undervalued-3543711",
        "imagepath": "",
        "date": "2025-09-20 18:26:38",
        "description": "As of 28 October 2021, the valuation grade for Blueprint Medicines Corp. has moved from fair to risky, indicating a shift towards a more negative outlook. Based on the available metrics, the company appears to be overvalued. The Price to Book Value stands at 24.13, while the EV to Capital Employed is 20.12, both suggesting a high valuation relative to its underlying assets. Additionally, the EV to Sales ratio of 14.82 further supports this assessment of overvaluation.\n\nIn comparison to its peers, Blueprint Medicines Corp. has a significantly negative EV to EBITDA of -52.59, while BridgeBio Pharma, Inc. shows a less severe -19.7279, indicating that Blueprint is underperforming relative to its industry. Moreover, Elanco Animal Health, Inc. is considered expensive with a P/E ratio of 19.2485, highlighting that Blueprint's valuation metrics are not competitive. Despite a strong year-to-date return of 48.43% com..."
      }
    ],
    "total": 7,
    "sid": "1151356",
    "stock_news_url": "https://www.marketsmojo.com/news/blueprint-medicines-corp-1151356"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Blueprint Medicines Corp. technically bullish or bearish?

2025-09-20 19:52:26

As of 4 June 2025, the technical trend for Blueprint Medicines Corp. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, while the Bollinger Bands also indicate bullishness in both periods. Moving averages are bullish on the daily chart, and Dow Theory confirms a bullish trend on both weekly and monthly levels. However, the weekly RSI is bearish, which suggests some short-term weakness. In terms of performance, the stock has returned 48.43% year-to-date compared to the S&P 500's 12.22%, and over three years, it has outperformed the benchmark with a return of 141.76% versus 70.41%. Overall, the technical indicators point to a bullish stance, albeit with some caution due to the bearish weekly RSI....

Is Blueprint Medicines Corp. overvalued or undervalued?

2025-09-20 18:26:38

As of 28 October 2021, the valuation grade for Blueprint Medicines Corp. has moved from fair to risky, indicating a shift towards a more negative outlook. Based on the available metrics, the company appears to be overvalued. The Price to Book Value stands at 24.13, while the EV to Capital Employed is 20.12, both suggesting a high valuation relative to its underlying assets. Additionally, the EV to Sales ratio of 14.82 further supports this assessment of overvaluation. In comparison to its peers, Blueprint Medicines Corp. has a significantly negative EV to EBITDA of -52.59, while BridgeBio Pharma, Inc. shows a less severe -19.7279, indicating that Blueprint is underperforming relative to its industry. Moreover, Elanco Animal Health, Inc. is considered expensive with a P/E ratio of 19.2485, highlighting that Blueprint's valuation metrics are not competitive. Despite a strong year-to-date return of 48.43% com...

View All News